Oskar Lehemaa's 'Birth' finds a Tallifornia backer for a body-horror spin on parenthood

Oskar Lehemaa has spent the last decade making the kind of films that travel through festivals like quiet rumours: small, patient, Eastern European, often untranslated. On 13 July 2026, Variety reported that the Estonian director has landed a Western backer for something noisier. Tallifornia Film Fund, a Los Angeles-based investor in elevated genre, has committed to Lehemaa's first English-language feature: Birth, a body-horror pitch that arrives with the blunt tagline "Grotesque and Terrifying." The project was presented at the Frontières Co-Production Market, the genre-adjacent forum that runs alongside the Cannes market week, and Variety's exclusive frames it as a deliberate inversion of the soft-focus pregnancy drama.

The premise is the kind that thrives on a single page of treatment: a couple, worn down by years of failed attempts, finally conceives. What follows is less a miracle than a slow, physical unravelling. Lehemaa's pitch makes the discomfort structural. Body horror, the mode that has spent two decades on the festival margins, has lately re-entered the main stage through genre retrospectives and the long tail of Bodies Bodies Bodies and The Substance. Birth arrives asking whether the form can carry something more domestic, more political, more private. Variety's exclusive notes the film follows the couple through a pregnancy that unsettles both the body and the relationship, pitched as "grotesque and terrifying" to potential co-producers.

A small industry, a louder pitch

Frontières is not Cannes. It is smaller, weirder, and more useful. Run out of Montreal with an outgoing edition that has co-financed an unusual share of the more abrasive genre projects of the last decade, the market is the kind of room where a director with a deliberately ugly pitch can find a producer willing to underwrite the discomfort. Variety's reporting frames the Lehemaa pitch as the sort of project that Frontières was built to surface: high concept, low budget, international in its financing and split across at least two tax jurisdictions. The Tallifornia commitment is the conversion mechanism.

Tallifornia Film Fund is a Los Angeles-based vehicle that has positioned itself, in recent industry coverage, as a backer of elevated genre work that larger studios will not touch. Its deals tend to be completion-heavy: a portion of the budget arrives once a project has a sales agent and a delivery plan, a structure that gives an emerging director leverage without requiring the financing of a fully greenlit studio feature. The fund's involvement does not, on its own, guarantee distribution; it does guarantee that the project can move from a Frontères pitch sheet into a production office.

The Estonian side of the production is not specified in the Variety report. Lehemaa has worked primarily through the Estonian Film Institute's funding rounds and through Tallinn-based producers who operate in the country's modest but persistent industry. Birth, as an English-language project, will likely still draw on Estonian tax-credit finance and, possibly, regional co-production support through the Baltic strand of Eurimages, the Council of Europe's pan-European fund. The Variety exclusive does not name the Estonian producer or co-producer, and the report does not state the budget.

What the pitch is selling

The body-horror genre has spent most of its recent history as a vehicle for political allegory. The most-watched contemporary examples use the body as a controlled site for arguments about identity, consumption or labour. Lehemaa's pitch, as Variety describes it, runs the allegory in the opposite direction: the body remains the site, but the argument is about reproduction itself, about the cost of arrival.

Variety characterises the script as a "grotesque and terrifying" take on pregnancy. The phrase matters. Soft-focus pregnancy drama, the commercial mode from which Birth is positioning itself as a corrective, has dominated streaming-platform slates for years. The alternative register has been more often handled by male directors attaching horror framing to reproductive anxiety, a tradition that runs through the Rosemary's Baby lineage and through more recent genre experiments. Lehemaa's pitch is unusual in placing the framing inside an Estonian arthouse register that has, historically, treated the body with a colder, more ethnographic eye.

It is also a pitch about partnership. Variety frames the central couple as the emotional and physical site of the story, which positions the script closer to relationship-horror than to a single-protagonist medical case study. The horror, on this reading, is relational as much as anatomical. The film's capacity to find a Western audience will depend on whether that relational register survives the translation into English.

Stakes, and what is not yet public

The deal, as Variety describes it, leaves most of the substantive questions open. There is no named sales agent attached to the project in the public reporting. There is no production start date, no cast and no Estonian-side producer credit. The script is described as having been "presented" at Frontières, which in market language means pitched, not yet locked, and may still face re-writes before a greenlight. The budget, by Variety's own silence, is undisclosed. These are not minor details: in elevated-genre financing, the difference between a project that moves and a project that stalls is most often a single named sales agent or a single closing tax credit.

What is public is that a European auteur with a body of work in his home industry has secured the interest of a US fund that has built a portfolio on paying for precisely this kind of discomfort. The structure matters more than the script. Frontières provides the room, Tallifornia provides the partial underwriting, and the next six to nine months will provide the closed financing, the attachment of a sales agent, and the casting decisions that will determine whether Birth arrives as a festival premiere in 2027 or joins the longer queue of elevated-genre projects that never complete.

What the Variety reporting does not address, and what the industry will want answered, is whether a body-horror pitch this confrontational can survive the marketing gauntlet. The films that Tallifornia has backed have tended to find their audiences in genre-friendly distributors willing to lean into discomfort. Birth's pivot into pregnancy will put its eventual distributor in a more mainstream set of conversations, including about which festivals to premiere at, which ratings board to submit to, and how to position the project to a press that is not always comfortable with the form. The pitch at Frontières is one battle. The marketing plan is the next.

, This piece focuses on the financing structure, the Frontières market context, and the genre positioning of the project, drawing solely on Variety's 13 July 2026 exclusive. The reporting does not include comments from Estonian producers, named sales agents, or the Tallifornia principals.